Quotient Limited (QTNT) Trading Up -6.7%

Shares of Quotient Limited (NASDAQ:QTNT) were up 6.7% during mid-day trading on Wednesday . The company traded as high as $5.14 and last traded at $4.51. Approximately 326,352 shares changed hands during trading, an increase of 39% from the average daily volume of 234,022 shares. The stock had previously closed at $4.84.

A number of analysts have recently issued reports on QTNT shares. BTIG Research reaffirmed a “buy” rating and set a $12.00 target price on shares of Quotient Limited in a research report on Thursday, August 31st. Zacks Investment Research raised Quotient Limited from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Finally, ValuEngine raised Quotient Limited from a “strong sell” rating to a “sell” rating in a research report on Friday, June 30th.

The company has a 50-day moving average price of $4.29 and a 200-day moving average price of $6.23. The stock’s market capitalization is $63.97 million.

Quotient Limited (NASDAQ:QTNT) last released its earnings results on Monday, August 7th. The company reported ($0.55) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.55). The firm had revenue of $6.83 million during the quarter, compared to analyst estimates of $5.70 million. Quotient Limited had a negative net margin of 381.66% and a negative return on equity of 13,050.41%. Analysts anticipate that Quotient Limited will post ($2.01) EPS for the current fiscal year.

In other news, insider D J. Paul E. Cowan sold 20,580 shares of the company’s stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $6.29, for a total transaction of $129,448.20. Following the completion of the transaction, the insider now owns 26,666 shares of the company’s stock, valued at $167,729.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider D J. Paul E. Cowan sold 45,032 shares of the company’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $6.57, for a total transaction of $295,860.24. Following the transaction, the insider now directly owns 26,666 shares of the company’s stock, valued at approximately $175,195.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 265,612 shares of company stock valued at $1,443,079. Company insiders own 29.00% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. New York State Common Retirement Fund acquired a new position in shares of Quotient Limited during the second quarter valued at about $101,000. Goldman Sachs Group Inc. acquired a new position in shares of Quotient Limited during the second quarter valued at about $104,000. Nationwide Fund Advisors acquired a new position in shares of Quotient Limited during the second quarter valued at about $111,000. The Manufacturers Life Insurance Company acquired a new position in shares of Quotient Limited during the second quarter valued at about $177,000. Finally, Rhumbline Advisers acquired a new position in shares of Quotient Limited during the second quarter valued at about $201,000. 57.68% of the stock is owned by institutional investors and hedge funds.

WARNING: This news story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/09/15/quotient-limited-qtnt-trading-up-6-7.html.

Quotient Limited Company Profile

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.

Receive News & Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply